Safety and efficacy of allogeneic hematopoietic stem cell transplantation for refractory hematological malignancies with plerixafor-combined myeloablative conditioning

Trial Profile

Safety and efficacy of allogeneic hematopoietic stem cell transplantation for refractory hematological malignancies with plerixafor-combined myeloablative conditioning

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 10 Dec 2016

At a glance

  • Drugs Plerixafor (Primary) ; Antineoplastics
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Most Recent Events

    • 05 Jun 2014 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
    • 10 Dec 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top